Type: Oral
Session: 102. Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research, hematopoiesis, metabolism, Biological Processes, pathogenesis
We identified and explored several structural elements within the ERFE N-terminus. All models of BMP interaction with ERFE predicted the binding of a tryptophan-containing hydrophobic helix of ERFE to a deep groove formed at the interface of all BMP dimers (BMP2/6 in cyan/green, ERFE in magenta; interaction in callout box, left panel). The highly evolutionarily conserved hydrophobic region (residues 81-86) was required for bioactivity and for tight binding to BMPs. Deletion of the hydrophobic segment or W82A substitution of the strictly conserved tryptophan ablated bioactivity and greatly decreased the binding of ERFE to BMPs. In nearly all models, a positively-charged cationic segment and the collagen-like segment made no contact with BMPs. However, the cationic segment was required for activity (right panel) although its deletion had only minor effect on binding to BMP. The specific arrangement of arginines and lysines in this segment did not matter for bioactivity or binding. We showed that the segment was essential for heparin-binding and propose that it may serve to concentrate ERFE at the site of its activity. Deletion of the collagen segment or the more distal helical segment (green) impaired IC50 much less (50-100fold) but also substantially disrupted monomeric binding. The collagen segment forms a triple helix in trimeric models of ERFE, but the helix is disrupted by BMP binding.
Secondary binding contacts between ERFE and BMPs in AF2 varied depending on the oligomeric state of erythroferrone. In monomers and dimers, the helical segment made contact with the contralateral wing of the BMP dimer. Remarkably, both primary and secondary binding interactions of BMPs were structurally similar to the BMP interactions with their receptors or known antagonists.
Nondenaturing PAGE suggested that the predominant form of ERFE was a hexamer. The AF2 structure of hexameric ERFE (magenta) with three molecules of BMP2/6 (cyan-green) showed that each BMP heterodimer bound two ERFE proximal helical segments including 81-86, within each of its two BMP2/6 interfacial grooves (left panel) but unlike in monomers and dimers, the secondary interaction did not involve the distal helical segment but the globular heads (red trimers on each side).
Despite their reductionist nature, these studies provide useful structural predictions that should allow better pharmacologic targeting of this important erythroid regulator of iron homeostasis.
Disclosures: Nemeth: Ionis Pharma: Consultancy; Protagonist Pharma: Consultancy; Intrinsic LifeSciences: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Vifor Pharma: Consultancy; Silarus Pharma: Consultancy, Current holder of stock options in a privately-held company; AstraZeneca and Fibrogen: Consultancy; Chiesi: Consultancy; Chugai: Consultancy; GSK: Consultancy; Novo Nordisk: Consultancy; Disc Medicine: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees. Ganz: Disc Medicine: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Ionis Pharma: Consultancy; Intrinsic LifeSciences: Consultancy, Current equity holder in private company; Silarus Pharma: Consultancy, Current holder of stock options in a privately-held company; BristolMyersSquibb: Consultancy; Avidity Bio: Consultancy; Dexcel: Consultancy; Chugai: Consultancy; GSK: Consultancy.